Lege Artis Medicinae

[Treatment of chronic Pseudomonas aeruginosa lung infections in cystic fibrosis with inhaled tobramycin]


JULY 20, 2015

Lege Artis Medicinae - 2015;25(06-07)

[BACKGROUND - Intermittent or chronic pulmonary infections caused by Pseudo­monas aeruginosa (Pa) deteriorate clinical status and worsen lung function in patients with cystic fibrosis (CF). The prognosis of the disease and life expectancy of patients are substantially dependent on lung infections and inflammation; therefore the primary goal of the treatment is the early termination of the infection. PATIENTS AND METHODS - Efficacy of tobramycin (TOBI® 300 mg/5 mL solution for inhalation, henceforth TOBI®) inhalation in Pa pulmonary infections was studied in a non-interventional, observational, open-label, single-arm trial in subjects with CF. Fifty-three patients aged six to 31 years (averaged 15.8 years) were enrolled into the study. Three treatment cycles of TOBI® inhalation (28 days on drug, 28 days off drug) plus 6 months observational period were evaluated. Primary endpoint was changing in the predictive values of forced expiratory volume in 1 sec (FEV1) compared to the initial values after three cycles of the treatment. Secondary endpoints were changing in the FEV1 predictive values at the end of the complete study compared to the initial values; ratios of patients with decreased density of originally Pa-positive result of sputum culture; as well as safety and tolerability of the TOBI® treatment. RESULTS - FEV1 and FEV1% results were unchanged comparing to the initial values at the end of the treatment and after the observational period in the whole study population. However, sputum cultures became negative in 47.2% of all subjects as a result of the treatment, and the FEV1 values were gradually increased in these patients: after the third treatment cycle plus 160 mL, and at the end of the study plus 110 mL comparing to the initial values. Similar considerable increase was detected in the predictive FEV1% in this sub-group: after the first cycle plus 5.2%, at the end of third cycle plus 7%, after the observational period above 3.8% considering the starting results. CONCLUSIONS - TOBI® inhalation proved to be effective in improvement of lung function results and eradication of infection in our patients with Pa positive CF. The treatment was well tolerated and safe.]



Related contents

Lege Artis Medicinae



[In chronic obstructive airway diseases there are several unsolved questions regarding the early diagnosis, monitoring treatment, simple detection of exacerbations and the questions of differential diagnosis. These problems indicate the need for the development of new diagnostic methods and their application in clinical practice. This need is further emphasized by the fact that in most chronic airway diseases, including asthma and chronic obstructive pulmonary disease inflammation has a central role in the pathomechanism and its suppression is the main aim of treatment, but so far, we do not have adequate method for the assessment of inflammation intensity in clinical practice. In recent decades non-invasive sampling techniques directly from the airways have made a progress in respiratory research and at present some of them are available for clinical use. Among these techniques sputum induction, measurement of exhaled biomarkers including exhaled nitric oxide and mediators in exhaled breath condensate samples are used increasingly. The present review summarises our current knowledge on these methods and the most important findings obtained by their applications.]

Lege Artis Medicinae

[Treatment of pneumothorax in cystic fibrosis]


[INTRODUCTION - More and more children affected by cystic fibrosis reach adulthood. The frequency of complications, such as pneumothorax, increases parallel with the long disease course. PATIENTS AND METHODS - The treatment of 17 manifestations of pneumothorax in 10 young adult cystic fibrosis patients in our institute was analysed retrospectively. RESULTS - Depending on the extension of pneumothorax and the clinical state of the patients the first choice of the treatment was observation alone in 6 cases, insertion of pleuracan in 3 cases and tube thoracostomy in 8 cases. Due to ineffective suction, thoracotomy was necessary in 6 patients, bilaterally in 3 cases. CONCLUSION - The outcome of conservative treatment even in "small, circumscribed pneumothorax" cases of symptom-free patients is uncertain and risky. Insertion of a pleuracan is recommended only in urgent, life-threatening cases, but definitive result should not be expected. If possible, chest drainage should be chosen as the first procedure. After 5-7 days of ineffective chest suction, thoracotomy is mandatory. Recurrence of the pneumothorax is direct indication for surgery. Antibiotic treatment is suggested for the duration of drainage, as well as for the surgical procedure.]

Lege Artis Medicinae

[Ceftazidime - over ten years in the clinical practice]

SZALKA András, PRINZ Gyula

[This review discusses the principal features of ceftazidime based on the ten years experience since the introduction of the drug in the clinical practice: its broad antibacterial spectrum including Pseudomonas aeruginosa, favourable pharmacokinetics, wide range of indications, excellent clinical efficacy using empiric treatment or elective therapy and safety profile. ]

Lege Artis Medicinae

[Evaluation of mutations in cystic fibrosis]

NÉMETI Margit, PAPP Zoltán

[The frequency of the most common mutations of the CFTR gene was studied in families having children with cystic fibrosis. This study included 40 Hungarian families with a total of 140 family members. The results of mutation and haplotype analysis demonstrate that the most frequent mutation in the Hungarian cystic fibrosis population is the F508 which accunts for 70% of all the mutations. The most frequently occurring haplotype is B: 95,7% of the F508 CF chromosomes and 36% of the non-F508 chromosomes are associated with the haplotype B (KM-19: allele 2, XV-2c: allele 1). The molecular genetic analysis of CF families based on the study of the CFTR gene's mutations makes possible an improved prenatal diagnosis in high risk pregnancies. ]

Lege Artis Medicinae


LUDWIG Endre, KONKOLY Thege Marianne

[INTRODUCTION - The antibiotic sensitivity of Pseudomonas aeruginosa isolates in nosocomial infections was determined in a prospective multicenter study in Hungary. METHODS - The sensitivity of 441 nonduplicated Pseudomonas aeruginosa isolates were determined by E-test methodology. Antibiotic sensitivities were determined according to the NCCLS standard. RESULTS - The sensitivity of isolates decreased compared to the results of 2000 surveillance data (meropenem 83 vs 76%, imipenem 82 vs 67%, ceftazidime 80,2 vs 78%, piperacillin/tazobactam 86.3 vs 83%, amikacin 88.2 vs 79%, ciprofloxacin 75,9 vs 68%). The highest resistance rates were detected at the intensive care units and in case of isolates from bloodstream infections. CONCLUSIONS - The antibiotic sensitivity of Pseudomonas aeruginosa isolates decreased in the last three years and the high resistance rates detected in intensive care units and of invasive strains are of special concern. For effective therapy antibiotics should be used in high doses and betalactams given in prolonged infusions might be more efficacious than administered in bolus. In case of probable Pseudomonas infections the use of two effective antipseudomonas agents is recommended. Prudent use of the antibiotics and effective infection control are needed to prevent the further loss of activity of these antimicrobial agents.]